Market Overview

Regeneron Pharmaceuticals Spokesperson Declines Comment on Earlier Takeover Chatter

Share:
Related REGN
Leerink Is Back On Board The Biotech Train
Here Are The Most Notable Insider Transactions Hitting The Market
Related SNY
Merck, Sanofi Exploring Potential End To Joint Venture In Europe
EXCLUSIVE: Inovio Plans On Producing Zika Vaccine By Q3 2016, Ready For Phase 1 Study By Q4
Are There Any Small Biotechnology Companies With An Answer To The Zika Virus Question? (Seeking Alpha)

Regeneron (NASDAQ: REGN) spokesperson Peter Dworkin, while declining comment on earlier takeover chatter involving Sanofi (NYSE: SNY), did say that the two companies have a solid working relationship and have stated it would be advantageous to keep the relationship going as it is now, as separate companies.

Sanofi is Regeneron's largest shareholder currently. There is a standstill agreement in place preventing Sanofi from acquiring more than 30% of Regeneron's shares.

Regeneron shares spiked to a high of $145.81 on Thursday.

Posted-In: News Rumors M&A Movers

 

Related Articles (REGN + SNY)

View Comments and Join the Discussion!

Get Benzinga's Newsletters